Information
1 Sangwon 12-gil, Seongdong-gu, Seoul, South Korea
+82 31-852-0107
-
-
Overview
- Summary
- A company specializing in the research, development, and manufacturing of orthopedic medical devices, aiming to pioneer new medical service market areas by integrating new bio-businesses. Efforts to increase sales through strengthening sales and marketing organizations and expanding the portfolio of biomaterials and convergence medical devices. Plans to launch patient-specific cage services and enter the pain and spinal endoscopy market through electrical and electronic R&D. A profile of a company specializing in the research and manufacturing of in-body implants.A company specializing in the research, development, and manufacturing of orthopedic medical devices, aiming to pioneer new medical service market areas by integrating new bio-businesses. Efforts to increase sales through strengthening sales and marketing organizations and expanding the portfolio of biomaterials and convergence medical devices. Plans to launch patient-specific cage services and enter the pain and spinal endoscopy market through electrical and electronic R&D. A profile of a company specializing in the research and manufacturing of in-body implants.
- Key Products/Technologies
- Possession of diverse product lines in orthopedics and spine, including spinal fixation devices, fracture treatment devices, and minimally invasive medical devices. Development and manufacturing of patient-specific interbody fusion (PSIF) cages, produced using 3D printers based on patient X-ray, CT, and MRI data. Application of porous structures to promote natural bone growth, maximizing bone fusion speed and post-surgical stability. Acquisition of US FDA 510(k) clearance for the spinal fusion device 'UniSpace® TPLIF Cage'. Securing positive evaluations from medical professionals for high-value products such as cervical cages. Successful market entry of the 'Velo' line-up of spinal bone graft materials, combined with the regenerative medicine technology of its parent company, CGBIO. Development of bone fixation screws utilizing biodegradable magnesium and completion of 3D Ti Printing Cage development. Efforts in developing a smart pedicle screw system applying Raman sensors. Acquisition of technology for next-generation medical devices capable of non-surgical cervical pain treatment and spinal pain treatment through Balloon Catheter. Acquisition of patent licenses for minimally invasive spinal surgery technology and medical devices from US neurosurgeon Dr. Robert S. Bray, Jr..Possession of diverse product lines in orthopedics and spine, including spinal fixation devices, fracture treatment devices, and minimally invasive medical devices. Development and manufacturing of patient-specific interbody fusion (PSIF) cages, produced using 3D printers based on patient X-ray, CT, and MRI data. Application of porous structures to promote natural bone growth, maximizing bone fusion speed and post-surgical stability. Acquisition of US FDA 510(k) clearance for the spinal fusion device 'UniSpace® TPLIF Cage'. Securing positive evaluations from medical professionals for high-value products such as cervical cages. Successful market entry of the 'Velo' line-up of spinal bone graft materials, combined with the regenerative medicine technology of its parent company, CGBIO. Development of bone fixation screws utilizing biodegradable magnesium and completion of 3D Ti Printing Cage development. Efforts in developing a smart pedicle screw system applying Raman sensors. Acquisition of technology for next-generation medical devices capable of non-surgical cervical pain treatment and spinal pain treatment through Balloon Catheter. Acquisition of patent licenses for minimally invasive spinal surgery technology and medical devices from US neurosurgeon Dr. Robert S. Bray, Jr..
- In the dental implant sector, the 'Urudent' dental implant product, utilizing Daewoong Pharmaceutical's intellectual property, is scheduled for launch in Q1 2026. Internalization of key implant structures, fixtures (Dental Ocean) and abutments (GDS, All Abutment), through acquisitions. Strengthening the product portfolio based on digital dentistry.In the dental implant sector, the 'Urudent' dental implant product, utilizing Daewoong Pharmaceutical's intellectual property, is scheduled for launch in Q1 2026. Internalization of key implant structures, fixtures (Dental Ocean) and abutments (GDS, All Abutment), through acquisitions. Strengthening the product portfolio based on digital dentistry.
- In the electrical and electronic and other fields, possession of product lines for surgical catheters and electrosurgical devices. Participation in AMI (Advanced Metering Infrastructure) and renewable energy projects in the electrical energy business division. Securing 'visualization technology' through the acquisition of Solendos, a company specializing in spinal endoscopy equipment. Possession of endoscopy equipment and solutions optimized for bi-directional endoscopic surgery, inheriting 100 years of optical technology from Germany's MGB Endoscopy. Plans to present a new spinal surgery environment combining AI and software capabilities. Scheduled launch of ECM skin booster ODM business in Q3 2026.In the electrical and electronic and other fields, possession of product lines for surgical catheters and electrosurgical devices. Participation in AMI (Advanced Metering Infrastructure) and renewable energy projects in the electrical energy business division. Securing 'visualization technology' through the acquisition of Solendos, a company specializing in spinal endoscopy equipment. Possession of endoscopy equipment and solutions optimized for bi-directional endoscopic surgery, inheriting 100 years of optical technology from Germany's MGB Endoscopy. Plans to present a new spinal surgery environment combining AI and software capabilities. Scheduled launch of ECM skin booster ODM business in Q3 2026.
- Core Advantages
- Establishment of a global quality management system through MDSAP (Medical Device Single Audit Program) certification. Recognition of conformity to quality standards in four countries: the US, Japan, Australia, and Brazil. Capability to manage quality throughout the entire process from product development to production, supply, and after-sales service, meeting global regulatory standards.Establishment of a global quality management system through MDSAP (Medical Device Single Audit Program) certification. Recognition of conformity to quality standards in four countries: the US, Japan, Australia, and Brazil. Capability to manage quality throughout the entire process from product development to production, supply, and after-sales service, meeting global regulatory standards.
- Acquisition of patient-specific solutions and 3D printing technology. Acquisition of manufacturing product approval from the Ministry of Food and Drug Safety for patient-specific interbody fusion cages optimized for patient anatomical structures. Completion of cervical interbody fusion cage development using 3D printing manufacturing technology.Acquisition of patient-specific solutions and 3D printing technology. Acquisition of manufacturing product approval from the Ministry of Food and Drug Safety for patient-specific interbody fusion cages optimized for patient anatomical structures. Completion of cervical interbody fusion cage development using 3D printing manufacturing technology.
- Establishment of a strong foundation for expanding the CDMO (Contract Development and Manufacturing Organization) business. Expansion of production capacity by over 300% with the completion of the new Uijeongbu factory, securing an annual production capacity of 600,000 units. Potential for further expansion to up to 800,000 units with the introduction of automated facilities. Aim to secure a competitive advantage in the global implant CDMO market.Establishment of a strong foundation for expanding the CDMO (Contract Development and Manufacturing Organization) business. Expansion of production capacity by over 300% with the completion of the new Uijeongbu factory, securing an annual production capacity of 600,000 units. Potential for further expansion to up to 800,000 units with the introduction of automated facilities. Aim to secure a competitive advantage in the global implant CDMO market.
- Creation of synergy effects through strategic collaboration with the parent company, CGBIO. Strengthening domestic and international market competitiveness by combining CGBIO's distribution network with its own product and production capabilities. Successful market entry of the 'Velo' line-up of spinal bone graft materials and FDA approval of the 'UniSpace' spinal fusion device optimized for 'Novosis Putty'. Expansion into the regenerative medicine-based fracture treatment market through an exclusive supply agreement for 'Novosis Trauma' with Johnson & Johnson MedTech.Creation of synergy effects through strategic collaboration with the parent company, CGBIO. Strengthening domestic and international market competitiveness by combining CGBIO's distribution network with its own product and production capabilities. Successful market entry of the 'Velo' line-up of spinal bone graft materials and FDA approval of the 'UniSpace' spinal fusion device optimized for 'Novosis Putty'. Expansion into the regenerative medicine-based fracture treatment market through an exclusive supply agreement for 'Novosis Trauma' with Johnson & Johnson MedTech.
- Business diversification strategy expanding from orthopedic implant fields to dental implants and spinal endoscopy markets. Strengthening portfolio and expanding market dominance through acquisitions of key technology companies such as Solendos, Dental Ocean, and All Abutment. Capability in developing new material medical devices and applying advanced manufacturing technologies.Business diversification strategy expanding from orthopedic implant fields to dental implants and spinal endoscopy markets. Strengthening portfolio and expanding market dominance through acquisitions of key technology companies such as Solendos, Dental Ocean, and All Abutment. Capability in developing new material medical devices and applying advanced manufacturing technologies.
- Target Industrie
- Development and supply of implants and surgical instruments in the orthopedic and spinal surgery fields.Development and supply of implants and surgical instruments in the orthopedic and spinal surgery fields.
- Expansion of business into the dental implant market.Expansion of business into the dental implant market.
- Entry into the bone graft and fracture treatment fields utilizing regenerative medicine technology.Entry into the bone graft and fracture treatment fields utilizing regenerative medicine technology.
- Participation in AMI (Advanced Metering Infrastructure) and renewable energy projects in the electrical energy business division.Participation in AMI (Advanced Metering Infrastructure) and renewable energy projects in the electrical energy business division.
- Planned entry into the ECM skin booster ODM business in the aesthetics sector.Planned entry into the ECM skin booster ODM business in the aesthetics sector.
- Major Markets
- Japan, Malaysia, Indonesia, Thailand, Middle East, Southeast Asia, China (clinical completion of biodegradable magnesium bone fixation screws)Japan, Malaysia, Indonesia, Thailand, Middle East, Southeast Asia, China (clinical completion of biodegradable magnesium bone fixation screws)
- EuropeEurope
- United StatesUnited States
- AustraliaAustralia
- BrazilBrazil
- Certifications/Patents
- Proof of global quality management system through MDSAP (Medical Device Single Audit Program) certification acquisition. Recognition of conformity to quality standards in four countries: the US, Japan, Australia, and Brazil.Proof of global quality management system through MDSAP (Medical Device Single Audit Program) certification acquisition. Recognition of conformity to quality standards in four countries: the US, Japan, Australia, and Brazil.
- Acquisition of manufacturing product approval from the Ministry of Food and Drug Safety for patient-specific interbody fusion (PSIF) cages.Acquisition of manufacturing product approval from the Ministry of Food and Drug Safety for patient-specific interbody fusion (PSIF) cages.
- Acquisition of US FDA 510(k) clearance for the spinal fusion device 'UniSpace® TPLIF Cage'.Acquisition of US FDA 510(k) clearance for the spinal fusion device 'UniSpace® TPLIF Cage'.
- Securing US FDA approval for Solendos' spinal endoscopy surgical system and related surgical instrument sets.Securing US FDA approval for Solendos' spinal endoscopy surgical system and related surgical instrument sets.
- Acquisition of patent licenses for minimally invasive spinal surgery technology and medical devices from US neurosurgeon Dr. Robert S. Bray, Jr..Acquisition of patent licenses for minimally invasive spinal surgery technology and medical devices from US neurosurgeon Dr. Robert S. Bray, Jr..
- Acquisition of 'Family-Friendly Excellent Company' certification, organized by the Ministry of Gender Equality and Family.Acquisition of 'Family-Friendly Excellent Company' certification, organized by the Ministry of Gender Equality and Family.
- Awarded 'Work-Study Parallel Excellent Company' appreciation plaque from the Deputy Prime Minister and Minister of Education, and the Minister of Employment and Labor.Awarded 'Work-Study Parallel Excellent Company' appreciation plaque from the Deputy Prime Minister and Minister of Education, and the Minister of Employment and Labor.
- Capability in analyzing and responding to core patents for minimally invasive therapeutic devices using plasma.Capability in analyzing and responding to core patents for minimally invasive therapeutic devices using plasma.
Introduction
Location
1 Sangwon 12-gil, Seongdong-gu, Seoul, South Korea
클릭하여 위치 살펴보기
